Mode
Text Size
Log in / Sign up
N/A Completed N=258 Randomized Screening

Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer

Source: ClinicalTrials.gov NCT01988376 ↗
Enrolled (actual)
258
Serious AEs
0.0%
Results posted
Nov 2018
Primary outcomePrimary: the Percentage of Smears, That Were Difficulty in Making a Definite Diagnosis — 0; 0 percentage of smears

Summary

Background/Purpose: This is a large scale, multicenter randomized clinical trial to assess the feasibility of using SurePath® in cervical cancer patients after radiation therapy by comparing the incidence of unsatisfactory smear and the accuracy of detecting cervicovaginal lesions between the SurePath® and the conventional smear. Patients and Methods: The investigators will invite all women who had received radiotherapy for cervical cancer in the investigators outpatient clinics. All enrolled cases will ask to receive randomly the SurePath® or the conventional smear. Expected Results: The investigators will get the incidence of unsatisfactory smear and the accuracy of detecting cervicovaginal lesions between the SurePath® and the conventional smear in patients who underwent radiotherapy.

Outcome Measures

OutcomeResultp-value
PRIMARY
the Percentage of Smears, That Were Difficulty in Making a Definite Diagnosis
0; 0

Eligibility Criteria

Inclusion Criteria

  • All women who had received radiotherapy for cervical cancer in our outpatient clinics.
  • Prior to joining test subjects for 90 days or more earlier had received a complete pelvic radiation therapy, including treatment of the cervix or vagina.
  • Subjects with radiation therapy (including combined chemical and radiation therapy or postoperative adjuvant [chemical] radiation therapy) for their first treatment.

Exclusion Criteria

  • recurrence of cervical cancer
  • hormone treatment within 90 days
  • vaginal vault or cervix topical treatment within 90 days.
  • Subjects had or now have other malignancies
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01988376). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search